Unlock instant, AI-driven research and patent intelligence for your innovation.

Composition for preventing or treating hepatitis containing monoacetyl diacylglycerol compound

A technology of monoacetyldiacylglycerol and a composition is applied in the field of compositions for preventing or treating hepatitis, and can solve the problems of failing to make other progress, failing to prove the therapeutic effect of liver cancer, and increasing the discharge of carcinogens.

Inactive Publication Date: 2019-08-13
ENZYCHEM LIFESCI CORP
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, although the extract extracted from green tea increased the activity of UDP-glucuronosyl transferase (UDP-glucuronosyl transferase), it was shown to increase the excretion of carcinogens in the liver (see: A.Bu-Abbas et al., Food and Chemical Toxicology,33(1):27-30,1995; O.S.Sohn et al., Food and Chemical Toxicology,36:617-621,1998), but failed to confirm its therapeutic effect on actual liver cancer, in addition Research on extracts that can improve liver disease has also failed to make other progress

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for preventing or treating hepatitis containing monoacetyl diacylglycerol compound
  • Composition for preventing or treating hepatitis containing monoacetyl diacylglycerol compound
  • Composition for preventing or treating hepatitis containing monoacetyl diacylglycerol compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] [Example 1] Preparation of control and experimental groups

[0055] The mice were randomly divided into three groups, namely control group, ConA treatment group and PLAG pretreatment group. The ConA and PLAG were all dissolved in PBS (phosphate buffer saline) and used. PBS or PLAG was administered orally to the mice, and 20 mg / kg BW of ConA was injected intravenously into the ConA-treated group and the PLAG-pretreated group 2 hours later. Then, PLAG was orally administered to the mice in an amount of 100 mg / kg BW. Here, BW means body weight.

experiment example 1

[0056] [Experimental example 1] Analysis of plasma and tissue cytokines (cytokine)

[0057] A blood sample was obtained by administering ConA to the mouse of Example 1, and performing cardiac puncture (cardiac puncture) 18 hours later, and centrifuging at 3000 rpm for 10 minutes. To measure cytokines in liver tissue lysates, animals were sacrificed and livers were washed with PBS. Liver was homogenized and filtered in PBS using a 70 μm mesh cell strainer (BD Falcon cell strainer, BD Biosciences, Bedford, MA). Furthermore, the supernatant was centrifuged at 2000 rpm for 5 minutes and collected. Cell aggregates in the lower layer were resuspended in PBS and analyzed by complete blood cell count (CBC). Plasma samples and supernatants of liver lysates were maintained at -20°C until cytokines were detected. The concentrations of IL-6, IL-10, IL-4, MIP-2 and IFNγ were measured using an enzyme-linked immunosorbent assay kit (Enzyme Linked Immunosorbent Assay Kit).

[0058] fi...

experiment example 2

[0060] [Experimental example 2] Hematological analysis of whole blood and liver samples

[0061] Whole blood and liver samples were collected 18 hours after ConA was administered to the mice of Example 1. Liver harvested from mice was homogenized as described in Experimental Example 1. Blood test (Complete blood count, CBC) analysis includes quantification of all white blood cells, neutrophils of all white blood cells, and some lymphocytes. Hematological analysis was performed using Mindray BC5300 (Shenzhen Mindray Biomedical Electronics, China).

[0062] Figure 4 is a graph showing changes in neutrophils and leukocytes in blood (A) and liver tissue (B) when the composition of the present invention is administered. Such as Figure 4 As shown, based on the number of circulating leukocytes in mice stimulated by Con-A slightly decreased, in the PLA additional administration group, the number of circulating neutrophils increased significantly ( Figure 4 A). Furthermore, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is a composition for preventing or treating hepatitis containing a monoacetyl diacylglycerol compound which not only can effectively prevent and treat hepatitis, but also is safe without anyside effects when used. The composition contains a monoacetyl diacylglycerol compound represented by chemical formula 1 in the specification as an active ingredient. In chemical formula 1 in the specification, R1 and R2 are independently a fatty acid group having a carbon number of 14 to 22.

Description

technical field [0001] The present invention relates to a composition for preventing or treating hepatitis containing a monoacetyl diacylglycerol compound, more specifically, to a composition for preventing or treating hepatitis containing a monoacetyl diacylglycerol compound, which Not only can it effectively prevent and treat hepatitis, but it is safe and has no side effects when used. Background technique [0002] As one of the most important metabolic organs in the internal organs of the body, the liver performs important functions such as secreting bile, storing nutrients, detoxifying, etc. Therefore, when abnormalities occur in the liver, the following metabolic disorders occur: such as bile metabolism, lipid metabolism, protein and nitrogen Metabolism, amino acid metabolism, protein metabolism and hepatic encephalopathy, vitamin metabolism, malabsorption, etc. Hepatitis, fatty liver, cirrhosis, etc. can cause liver disease to worsen. So far, known liver diseases inc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/231A23L33/10
CPCA23V2002/00A23V2200/30A61K31/231A61P1/16A23L33/12A23L33/10A61K38/2026A61K38/2053
Inventor 孙起荣尹善瑛郑宰旭金兴载
Owner ENZYCHEM LIFESCI CORP